PML and acute promyelocytic leukemia: In vivo pre-treatment with Bortezomib, a proteasome inhibitor, stabilized SUMO2/3 conjugates upon arsenic exposure in Pml-proficient livers or APL (Supplementary Fig. 2d and Supplementary Fig. 4b below).